Evidence map›Paper›PMID 40327138›Full record

ArticleCalcified tissue international2025

Gene Variants and Bisphosphonates Treatment in Pregnancy and Lactation-Associated Osteoporosis (PLO): A Retrospective Study of 22 Chinese Patients.

Ziyao Fu, Xiaolin Ni, Sirui Han, Mei Li, Ou Wang, Xiaoping Xing, Yan Jiang, Weibo Xia

Abstract read
PubMed Publisher
In one paragraph

Article in Calcified tissue international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Pregnancy and Lactation Associated Bone Fragility.Journal of the Endocrine Society · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ziyao FuDepartment of Endocrinology, Key Laboratory of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Dongcheng District, National Commission of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No.1, Wangfujing Street, Beijing, 100730, China.
Xiaolin NiDepartment of Endocrinology, Genetics and Metabolism, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.
Sirui HanDepartment of Endocrinology, Key Laboratory of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Dongcheng District, National Commission of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No.1, Wangfujing Street, Beijing, 100730, China.
Mei LiDepartment of Endocrinology, Key Laboratory of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Dongcheng District, National Commission of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No.1, Wangfujing Street, Beijing, 100730, China.
Ou WangDepartment of Endocrinology, Key Laboratory of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Dongcheng District, National Commission of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No.1, Wangfujing Street, Beijing, 100730, China.
Xiaoping XingDepartment of Endocrinology, Key Laboratory of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Dongcheng District, National Commission of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No.1, Wangfujing Street, Beijing, 100730, China.
Yan JiangDepartment of Endocrinology, Key Laboratory of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Dongcheng District, National Commission of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No.1, Wangfujing Street, Beijing, 100730, China. sinojenny@126.com.
Weibo XiaDepartment of Endocrinology, Key Laboratory of Endocrinology, State Key Laboratory of Complex Severe and Rare Diseases, Dongcheng District, National Commission of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Shuaifuyuan No.1, Wangfujing Street, Beijing, 100730, China. xiaweibo8301@163.com.ORCID http://orcid.org/0000-0001-7768-5536

Funding

Beijing Natural Science Foundation 7232120CAMS Innovation Fund for Medical Sciences (CIFMS) 2021-I2M-1-002National High Level Hospital Clinical Research Funding 2022-PUMCH-D-006the National Natural Science Foundation of China No.82270938the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2023-PT320-10
6 · The paper itself

Abstract

Pregnancy and lactation-associated osteoporosis (PLO) is a rare bone disorder with insufficient understanding on its pathogenesis and treatments. We retrospectively investigated 22 Chinese PLO patients diagnosed in our hospital. Whole exome sequencing was performed in 14 patients, and responses to bisphosphonates treatment were evaluated. The mean age of the patients was 30.8 ± 4.4 years. The mean number of vertebral fractures per patient was 4.0 ± 2.6. The bone mineral density (BMD) Z-scores were - 2.9 ± 0.9 at the lumbar spine (LS), - 1.7 ± 0.7 at the femoral neck, and - 1.8 ± 0.7 at the total hip. Trabecular bone score Z-score was - 2.2 ± 0.8. Genetic analysis identified relevant variants (RVs) in 11 of 14 patients, predominantly in LRP5, WNT1, and COL1A1/A2. Patients with RVs had significantly greater height loss (3.6 ± 2.1 cm vs. 0 cm, p = 0.028). All patients received bisphosphonate therapy, during which increases in BMD primarily at the LS were observed: 13.5 ± 8.8%, 17.8 ± 14.7%, 22.0 ± 17.0%, 27.0 ± 14.1% and 35.1 ± 18.5% at the 6-, 12-, 24-, 36-, and 48-month follow-ups. Patients with RVs demonstrated LS BMD percentage changes of 40.1 ± 22.1% (vs. no RVs group 26.2 ± 14.8%, p = 0.57) after 48-month follow-ups. In conclusion, our study highlights the significant clinical burden of PLO. Genetic RVs are prevalent in Chinese PLO patients. After bisphosphonate treatment, there is a significant increase in BMD, especially in LS. Patients with RVs have the potential of more robust therapeutic response.

Indexed as

Bone Density Conservation AgentsDiphosphonatesLactationOsteoporosisPregnancy ComplicationsAdultBone DensityChinaCollagen Type I, alpha 1 ChainEast Asian PeopleFemaleHumansLow Density Lipoprotein Receptor-Related Protein-5PregnancyRetrospective StudiesBone Density Conservation AgentsCollagen Type I, alpha 1 ChainDiphosphonatesLow Density Lipoprotein Receptor-Related Protein-5BisphosphonatesBone mineral densityGenePregnancy and lactation-associated osteoporosisTrabecular bone score

Identifiers

PMID40327138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.